Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

BACKGROUND Most cancers of the uterine cervix are squamous cell carcinomas. Although the incidence of such carcinomas of the uterine cervix has declined over time, that of cervical adenocarcinoma has risen in recent years. The extent to which human papillomavirus (HPV) infection and cofactors may explain this differential trend is unclear. METHODS We pooled data from eight case-control studies of cervical cancer that were conducted on three continents. A total of 167 case patients with invasive cervical adenocarcinoma (112 with adenocarcinoma and 55 with adenosquamous carcinoma) and 1881 hospital-based control subjects were included. HPV DNA was analyzed in cervical specimens with the GP5+/6+ general primer system followed by type-specific hybridization for 33 HPV genotypes. Blood samples were analyzed for chlamydial and herpes simplex virus 2 (HSV-2) serology. Multivariable unconditional logistic regression modeling was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs). All tests of statistical significance were two-sided. RESULTS The adjusted overall odds ratio for cervical adenocarcinoma in HPV-positive women compared with HPV-negative women was 81.3 (95% CI = 42.0 to 157.1). HPV 16 and HPV 18 were the two most commonly detected HPV types in case patients and control subjects. These two types were present in 82% of the patients. Cofactors that showed clear statistically significant positive associations with cervical adenocarcinoma overall and among HPV-positive women included never schooling, poor hygiene, sexual behavior-related variables, long-term use of hormonal contraception, high parity, and HSV-2 seropositivity. Parity had a weaker association with adenocarcinoma and only among HPV-positive women. Use of an intrauterine device (IUD) had a statistically significant inverse association with risk of adenocarcinoma (for ever use of an IUD compared with never use, OR = .41 [95% CI = 0.18 to 0.93]). Smoking and chlamydial seropositivity were not associated with disease. CONCLUSIONS HPV appears to be the key risk factor for cervical adenocarcinoma. HPV testing in primary screening using current mixtures of HPV types and HPV vaccination against main HPV types should reduce the incidence of this cancer worldwide.

[1]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[2]  L. Brinton,et al.  Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States) , 2001, Cancer Causes & Control.

[3]  S. Raab Can glandular lesions be diagnosed in pap smear cytology? , 2000, Diagnostic cytopathology.

[4]  N. Weiss,et al.  Endometrial cancer in relation to intra‐uterine device use , 1997, International journal of cancer.

[5]  F. X. Bosch,et al.  Environmental co-factors in HPV carcinogenesis. , 2002, Virus research.

[6]  L. Brinton,et al.  Intrauterine device use and endometrial cancer risk. , 1997, International journal of epidemiology.

[7]  S. Franceschi,et al.  Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case‐control study , 2003, International journal of cancer.

[8]  S. Franceschi,et al.  Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. , 2002, Journal of the National Cancer Institute.

[9]  E. Pirog,et al.  Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. , 2000, The American journal of pathology.

[10]  C. Meijer,et al.  Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. , 1995, British Journal of Cancer.

[11]  V. Moreno,et al.  Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study , 2002, The Lancet.

[12]  F. X. Bosch,et al.  Risk factors for cervical cancer in Thailand: a case-control study. , 1998, Journal of the National Cancer Institute.

[13]  O. Paltiel,et al.  IUD use and the risk of endometrial cancer. , 2002, European journal of obstetrics, gynecology, and reproductive biology.

[14]  N. Muñoz,et al.  The viral origin of cervical cancer in Rabat, Morocco , 1998, International journal of cancer.

[15]  L. Brinton,et al.  Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. , 2003, American journal of obstetrics and gynecology.

[16]  V. Moreno,et al.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.

[17]  D. Thomas,et al.  Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. , 1996, American journal of epidemiology.

[18]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[19]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[20]  M. Pike,et al.  Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix: results from a population-based case-control study (California, United States) , 1996, Cancer Causes & Control.

[21]  L. Brinton,et al.  Risk factors for cervical cancer by histology. , 1993, Gynecologic oncology.

[22]  Julian Peto,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[23]  H. Pfister,et al.  State of the art regarding evidence of the viral origin of cervical cancer. , 1991, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[24]  Thomas Db,et al.  Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. , 1991, International journal of cancer.

[25]  C. Key,et al.  The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. , 2000, Gynecologic oncology.

[26]  L. Brinton,et al.  Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. , 2000, Gynecologic oncology.

[27]  R. Ray,et al.  Oral Contraceptives and Invasive Adenocarcinomas and Adenosquamous Carcinomas of the Uterine Cervix , 1996 .

[28]  L. Brinton,et al.  Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix , 2003, Cancer.

[29]  M. Chang,et al.  Detection of human papillomavirus types in cervical adenocarcinoma by the polymerase chain reaction , 1998, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[30]  A. Berrington de González,et al.  Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis , 2004, British Journal of Cancer.

[31]  N. Muñoz,et al.  Prevalence and Risk Factors for Herpes Simplex Virus Type 2 Infection Among Middle-Age Women in Brazil and the Philippines , 2001, Sexually transmitted diseases.

[32]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[33]  L. Brinton,et al.  Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  M. Plummer,et al.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.

[35]  S. Wacholder,et al.  HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica , 2001, British Journal of Cancer.

[36]  E. Wilander,et al.  The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. , 2001, European journal of cancer.

[37]  D M Parkin,et al.  International trends in incidence of cervical cancer: II. Squamous‐cell carcinoma , 2000, International journal of cancer.

[38]  K. Rosenblatt,et al.  Intrauterine devices and endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. , 1996, Contraception.

[39]  N. Muñoz,et al.  HPV types and cofactors causing cervical cancer in Peru , 2001, British Journal of Cancer.

[40]  N. Muñoz,et al.  Human papillomavirus infection and invasive cervical cancer in Paraguay , 2000, International journal of cancer.

[41]  D. Grimes,et al.  Noncontraceptive Health Benefits of Intrauterine Devices: A Systematic Review , 2002, Obstetrical & gynecological survey.

[42]  K. Mishra,et al.  Evaluation of endometrial steroid receptors and cell mitotic activity in women using copper intrauterine device: Can Cu‐T prevent endometrial cancer? , 2004, The journal of obstetrics and gynaecology research.

[43]  N. Muñoz,et al.  Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. , 2003, Journal of the National Cancer Institute. Monographs.

[44]  L. Grégoire,et al.  Glandular lesions of the uterine cervix : Prognostic implications of human papillomavirus status , 1997 .

[45]  R. Peeling,et al.  Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case‐control study , 2004, International journal of cancer.

[46]  C. Meijer,et al.  The presence of high‐risk HPV combined with specific p53 and p16INK4a expression patterns points to high‐risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix , 2003, The Journal of pathology.

[47]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[48]  M. Plummer,et al.  Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study , 2003, Cancer Causes & Control.

[49]  R L Ashley,et al.  Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera , 1988, Journal of clinical microbiology.

[50]  J. Fraumeni,et al.  Epidemiology of cervical cancer by cell type. , 1987, Cancer research.

[51]  F. X. Bosch,et al.  Causes of cervical cancer in the Philippines: a case-control study. , 1998, Journal of the National Cancer Institute.

[52]  C. la Vecchia,et al.  Risk factors for adenocarcinoma of the cervix: a case-control study. , 1988, British Journal of Cancer.

[53]  G. Giles,et al.  Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. , 1995, British Journal of Cancer.

[54]  F. X. Bosch,et al.  Human papillomavirus and invasive cervical cancer in Brazil. , 1994, British Journal of Cancer.

[55]  V. Moreno,et al.  International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas , 1998, International journal of cancer.

[56]  D. Thomas,et al.  Intrauterine devices and endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. , 1996, Contraception.

[57]  C. la Vecchia,et al.  Intrauterine device use and risk of endometrial cancer. , 1994, British Journal of Cancer.

[58]  R. Verheijen,et al.  Cervical cancer in the Netherlands 1989–1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women , 2005, International journal of cancer.

[59]  S. Franceschi,et al.  Cervical carcinoma in Algiers, Algeria: Human papillomavirus and lifestyle risk factors , 2005, International journal of cancer.

[60]  V. Beral,et al.  Cervical cancer and use of hormonal contraceptives: a systematic review , 2003, The Lancet.

[61]  R. Peeling,et al.  Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. , 2002, The Journal of infectious diseases.

[62]  V. Moreno,et al.  Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study , 2002, The Lancet.

[63]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[64]  S. Granter,et al.  Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix , 2001, Cancer.

[65]  D. Thomas,et al.  Tubal sterilization and use of an IUD and risk of cervical cancer. , 2000, Journal of women's health & gender-based medicine.

[66]  W. Thompson,et al.  Intra‐uterine contraception and the risk of endometrial cancer , 1993, International journal of cancer.